About 12 results found for searched term "58-33-3" (0.395 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2317 | VX-702 | p38 MAPK |
| VX-702 is a highly selective inhibitor of p38 MAPKα with IC50 of 4-20 nM. | ||
| M3665 | Promethazine hydrochloride | Histamine Receptor |
| Promethazine hydrochloride is a potent histamine H1 receptor antagonist used as a sedative and antiallergic compound. | ||
| M6703 | EHNA hydrochloride | Adenosine Deaminase |
| EHNA hydrochloride is a adenosine deaminase inhibitor. | ||
| M11113 | (R,R)-Secoisolariciresinol diglucoside | Others |
| (R,R)-SDG | ||
| (R,R)-Secoisolariciresinol diglucoside ((R,R)-SDG) is a minor subtype of Secoisolariciresinol diglucoside present in flaxseed. (R,R)-Secoisolariciresinol diglucoside ((R,R)-SDG) has antioxidant properties, free radical scavenging activity, and DNA-radiation protection. (R,R)-Secoisolariciresinol diglucoside ((R,R)-SDG) inhibits myeloperoxidase (MPO) activity by inhibiting peroxidase and chloride cycles in inflammatory cells. | ||
| M17719 | Cabraleahydroxylactone | Triterpenoids |
| Cabraleahydroxylactone | ||
| M18519 | Rifampicin N-Oxide | Others |
| Rifampicin N-Oxide | ||
| M21675 | Cotosudil | ROCK |
| Cotosudil is a ROCK kinase inhibitor. Cotosudil can be used for glaucoma or ocular hypertension research. | ||
| M24693 | Detumomab | Others |
| SPECIFID | ||
| Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL). | ||
| M27658 | GSK-626616 | DYRK |
| GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM). GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia. | ||
| M28894 | Samuraciclib | CDK |
| CT7001; ICEC0942 | ||
| Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib has anti-tumor effects. | ||
| M29549 | Darizmetinib | p38 MAPK |
| Darizmetinib is an inhibitor of mitogen-activated protein kinase kinase (MAP2K). | ||
| M43783 | Salvileucantholide | Others |
| Salvileucantholide is a diterpenoid isolated from S. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
